Therapeutics Initiative |

25 Aug Sodium–Glucose Cotransporter 2 Inhibitors and the Risk of Below-Knee Amputation: A Multicenter Observational Study

Posted at 19:44h in PharmacoEpidemiology 0 Comments

Diabetes Care Aug 2020, dc200267; DOI: 10.2337/dc20-0267 Oriana Hoi Yun Yu, Sophie Dell’Aniello, Baiju R. Shah, Vanessa C. Brunetti, Jean-Marc Daigle, MichaelFralick, Antonios Douros, Nianping Hu, Silvia Alessi-Severini, Anat Fisher, Shawn C. Bugden, Paul E.Ronksley, Kristian...

23 Sep Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study

Posted at 21:50h in PharmacoEpidemiology 0 Comments

BMJ 2020; 370 DOI: https://doi.org/10.1136/bmj.m3342 (Published 23 September 2020) Kristian B Filion, Lisa M Lix, Oriana HY Yu, Sophie Dell’Aniello, Antonios Douros, Baiju R Shah, Audray St-Jean, Anat Fisher, Eric Tremblay, Shawn C Bugden, Silvia Alessi-Severini,...

28 Jul Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis

Posted at 19:55h in PharmacoEpidemiology 0 Comments

Annals of Internal Medicine 2020 July 28. DOI: 10.7326/M20-0289 Antonios Douros, MD, PhD; Lisa M. Lix, PhD; Michael Fralick, MD, PhD; Sophie Dell’Aniello, MSc; Baiju R. Shah, MD, PhD; Paul E. Ronksley, PhD; Eric Tremblay, BPharm,...

dipeptidyl peptidase 4 Tag

25 Aug Sodium–Glucose Cotransporter 2 Inhibitors and the Risk of Below-Knee Amputation: A Multicenter Observational Study

23 Sep Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study

28 Jul Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis

Contact

Subscribe for Updates